Cancer-testis antigen HCA587/MAGE-C2 interacts with BS69 and promotes its degradation in the ubiquitin-proteasome pathway

Biochemical and Biophysical Research Communications

Volumn 449, Issue 4, 2014, Pages 386-391

  Hao, Jiaqing ^a   Shen, Rui ^a   Li, Yan ^a   Zhang, Yu ^a   Yin, Yanhui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

BS69; Cancer testis antigen; HCA587; Ubiquitination

Indexed keywords

CANCER TESTIS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEASOME; PROTEIN BS69; PROTEIN HCA587; PROTEIN MAGE C2; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEK293 CELL LINE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; UBIQUITINATION;

BS69; CANCER-TESTIS ANTIGEN; HCA587; UBIQUITINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, NEOPLASM; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; HEK293 CELLS; HELA CELLS; HUMANS; INTERLEUKIN-6; LIM DOMAIN PROTEINS; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITINATION;

EID: 84902886167     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.05.078     Document Type: Article

References (34)

1. Y. Wang, K.J. Han, X.W. Pang, et al., Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies, J. Immunol. 169 (2002) 1102-1109 (Pubitemid 34753471)
2. S. Lucas, E.D. Plaen, T. Boon, MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression, Int. J. Cancer 87 (2000) 55-60 (Pubitemid 30368415)
3. B. Li, X.P. Qian, X.W. Pang, et al., HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma, Lab. Invest. 83 (2003) 1185-1192 (Pubitemid 37013053)
4. B. Li, Y. Wang, J. Chen, et al., Identification of a new HLA-A/0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587, Clin. Exp. Immunol. 140 (2005) 310-319 (Pubitemid 40559158)
5. Q. Xing, X.W. Pang, J.R. Peng, et al., Identification of new cytotoxic Tlymphocyte epitopes from cancer testis antigen HCA587, Biochem. Biophys. Res. Commun. 372 (2008) 331-335
6. D. Godelaine, J. Carrasco, F. Brasseur, et al., A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44, Cancer Immunol. Immunother. 56 (2007) 753-759
7. W. Ma, N. Vigneron, J. Chapiro, et al., A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy, Int. J. Cancer 129 (2011) 2427-2434
8. J.J. Chen, L.J. Zhang, W.G. Wen, et al., Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice, PLoS One 7 (2012) e47219
9. W. Liu, S. Cheng, S.L. Asa, et al., The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis, Cancer Res. 68 (2008) 8104-8112
10. B. Yang, S.M. O'Herrin, J. Wu, et al., MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGEpositive cell lines, Cancer Res. 67 (2007) 9954-9962 (Pubitemid 47621245)
11. J.M. Doyle, J. Gao, J. Wang, et al., MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases, Mol. Cell 39 (2010) 963-974
12. G. Hateboer, A. Gennissen, Y.F. Ramos, et al., BS69, a novel adenovirus E1Aassociated protein that inhibits E1A transactivation, EMBO J. 14 (1995) 3159- 3169
13. H. Masselink, R. Bernards, The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR, Oncogene 19 (2000) 1538-1546 (Pubitemid 30175675)
14. N.E. Ladendorff, S. Wu, J.S. Lipsick, BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb, Oncogene 20 (2001) 125-132 (Pubitemid 32142345)
15. O. Ikeda, Y. Sekine, A. Mizushima, et al., BS69 negatively regulates the canonical NF-kappaB activation induced by Epstein-Barr virus-derived LMP1, FEBS Lett. 583 (2009) 1567-1574
16. O. Ikeda, Y. Miyasaka, R. Yoshida, et al., BS69 cooperates with TRAF3 in the regulation of Epstein-Barr virus-derived LMP1/CTAR1-induced NF-kappaB activation, FEBS Lett. 584 (2010) 865-872
17. R. Zhuang, Y. Zhu, L. Fang, et al., Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2, Cancer Immun. 6 (2006) 7
18. W. Ma, C. Germeau, N. Vigneron, et al., Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2, Int. J. Cancer 109 (2004) 698-702 (Pubitemid 38405616)
19. A.C. Fontecedro, N. Nuber, D. Mihic-Probst, et al., Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients, PLoS One 6 (2011) e21418
20. L. von Boehmer, L. Keller, A. Mortezavi, et al., MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer, PLoS One 6 (2011) e21366
21. P. Deloukas, G.D. Schuler, G. Gyapay, et al., A physical map of 30,000 human genes, Science 282 (1998) 744-746
22. F. Mitelman, F. Mertens, B. Johansson, A breakpoint map of recurrent chromosomal rearrangements in human neoplasia, Nat. Genet. 15 (1997) 417-474
23. H. Yang, C. Zhang, X.S. Zhao, et al., Analysis of copy number variations of BS69 in multiple types of hematological malignancies, Ann. Hematol. 89 (2010) 959-964
24. L.H. Davies, D. Huntsman, M. Ruas, et al., EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer, Cell 115 (2003) 523-535 (Pubitemid 37506042)
25. G. Wei, A.E. Schaffner, K.M. Baker, et al., Ets-2 interacts with co-repressor BS69 to repress target gene expression, Anticancer Res. 23 (2003) 2173- 2178 (Pubitemid 36897179)
26. R.G. Ramsay, T.J. Gonda, MYB function in normal and cancer cells, Nat. Rev. Cancer 8 (2008) 523-534 (Pubitemid 351881853)
27. A. Biroccio, B. Benassi, I. D'Agnano, et al., C-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings, Am. J. Pathol. 158 (2001) 1289-1299 (Pubitemid 32281293)
28. M. Persson, Y. Andrén, J. Mark, et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 18740-18744
29. V.I. Sementchenko, C.W. Schweinfest, T.S. Papas, et al., ETS2 function is required to maintain the transformed state of human prostate cancer cells, Oncogene 17 (1998) 2883-2888 (Pubitemid 29010058)
30. N. Neznanov, A.K. Man, H. Yamamoto, et al., A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice, Cancer Res. 59 (1999) 4242-4246 (Pubitemid 29418736)
31. E. Sapi, M.B. Flick, S. Rodov, et al., Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factorstimulated invasion by BT20 breast carcinoma cells, Cancer Res. 58 (1998) 1027-1033 (Pubitemid 28182474)
32. E. Viré, C. Curtis, V.V. Davalos, et al., The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31, Mol. Cell 53 (2014) 806-818
33. L.A. Brown, K. Johnson, S. Leung, et al., Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers, Breast Cancer Res. Treat. 121 (2010) 347-354
34. C. Rodriguez, H.L. Davies, H. Vallès, et al., Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome, Clin. Cancer Res. 10 (2004) 5785-5791. (Pubitemid 39180956)